Epidemiology of venous thrombosis;Epidémiologie de la thrombose veineuse

Bulletin de l'Academie Nationale de Medecine

Volumn 187, Issue 1, 2003, Pages 19-33

  Emmerich, Joseph ^a   Vacheron, André ^b   Jaffiol, Claude ^b   Battin, Jacques ^b  

^a HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^b NONE

Author keywords

Epidemiology; Genetic; Venous thrombosis

Indexed keywords

ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR; ORAL CONTRACEPTIVE AGENT;

ADULT; AGED; ARTICLE; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; FEMALE; FRANCE; GENETIC POLYMORPHISM; GENETICS; HUMAN; IMMOBILIZATION; INCIDENCE; LUNG EMBOLISM; MALE; MIDDLE AGED; MUTATION; ORAL DRUG ADMINISTRATION; PREGNANCY; PREGNANCY COMPLICATION; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; RISK FACTOR; TRAVEL; VEIN THROMBOSIS;

ADMINISTRATION, ORAL; ADULT; AGED; ANTICOAGULANTS; BLOOD COAGULATION FACTORS; CONTRACEPTIVES, ORAL; FEMALE; FRANCE; HUMANS; IMMOBILIZATION; INCIDENCE; MALE; MIDDLE AGED; MUTATION; POLYMORPHISM, GENETIC; PREGNANCY; PREGNANCY COMPLICATIONS, CARDIOVASCULAR; PULMONARY EMBOLISM; RANDOMIZED CONTROLLED TRIALS; RECURRENCE; RISK FACTORS; TRAVEL; VENOUS THROMBOSIS;

EID: 0642336705     PISSN: 00014079     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0001-4079(19)34077-4     Document Type: Article

References (54)

1. HEIT J.A., SILVERSTEIN M.D., MOHR D.N., et al. - The epidemiology of venous thromboembolism in the community. Thromb Haemost, 2001, 86, 452-63.
2. LENSING A.W.A., PRANDONI P., PRINS M.H., BÜLLER H.R. - Deep vein thrombosis. Lancet, 1999, 353, 479-85.
3. OGER E. for the EPI-GETBO Study Group. - Incidence of venous thromboembolism : a community-based study in Western France. Thromb Haemost, 2000, 83, 657-60.
4. LINDBLAD B., STERNBY N.H., BERGQVIST D. - Incidence of venous thromboembolism verified by necropsy over 30 years. BMJ, 1991, 302, 709-11.
5. PRANDONI P., LENSING A.W.A., COGO A., CUPPINI S., VILLALTA S., CARTA M., et al. - The long-term clinical course of acute deep venous thrombosis. Ann Intern Med, 1996, 125, 1-7.
6. SCHULMAN S., RHEDIN A.S., LINDMARKER P., CARLSSON A., LARFARS G., NICOL P., et al. - A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. Duration of Anticoagulation Trial Study Group. N Engl J Med., 1995, 332, 1661-5.
7. KEARON C., GENT M., HIRSH J., WEITZ J., KOVACS M.J., ANDERSON D.R., et al. - A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med.,, 1999, 340 (12), 901-7.
8. KYRLE P.A., MINAR E., HIRSCHL M., BIALONCZYK C., STAIN M., SCHNEIDER B., et al. - High plasma levels of factor VIII and the risk of recurrent venous thromboembolism. N Engl J Med, 2000, 343, 457-62.
9. AGNELLI G., PRANDONI P., SANTAMARIA M.G., et al. - Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. N Engl J Med, 2001, 345, 165-9.
10. PINÈDE L., NINET J., DUHAUT P., et al. - Comparison of 3 and 6 months of oral anticoagulant therapy after a first episode of proximal deep vein thrombosis or pulmonary embolism and comparison of 6 and 12 weeks of therapy after isolated calf deep vein thrombosis. Circulation, 2001, 103, 2453-60.
11. ROSENDAAL F.R. - Venous thrombosis : a multicausal disease. Lancet, 1999, 353, 1167-73.
12. ROSENDAAL F.R. - Risk factors for venous thrombosis : prevalence, risk and interaction. Semin Hematol, 1997, 34, 171-87.
13. SELIGSOHN U., LUBETSKY A. - Genetic susceptibility to venous thrombosis. N Engl J Med, 2001, 344, 1222-31.
14. EMMERICH J. - Mécanismes et facteurs de risque de la maladie veineuse thrombo-embolique. Revue du Praticien, 1996, 46, 1203-10.
15. HULLEY S., GRADY D., BUSH T., et al. - Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA, 1998, 280, 605-13.
16. ELDOR A. - Thrombophilia, thrombosis and pregnancy. Thromb Haemost, 2001, 86, 104-11.
17. SAMAMA M.M., COHEN A.T., DARMON J.Y., et al. - A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. N Engl J Med, 1999, 341, 793-800.
18. BERNSTEIN C.N., BLANCHARD J.F., HOUSTON D.S., WAJDA A. - The incidence of deep venous thrombosis and pulmonary embolism among patients with inflammatory bowel disease : a population-based cohort study. Thromb Haemost, 2001, 85, 430-4.
19. EMMERICH J. - Le syndrome de la classe économique : mythe ou réalité et quelle prévention. Rev Med Intern, 2001, 22, 425-7.
20. GREAVES M. - Antiphospholipid antibodies and thrombosis. Lancet, 1999, 353, 1348-53.
21. ZORNBERG G.L., JICK H. - Antipsychotic drug use and risk of first-time idiopathic venous thromboembolism : a case-control study. Lancet, 2000, 356, 1219-23.
22. LOZINGUEZ O., ARNAUD E., BELEC L., et al. - Demonstration of an association between Chlamydia pneumoniae infection and venous thromboembolic disease. Thromb Haemost, 2000, 83, 887-91.
23. BERTINA R.M. - Genetic approach to thrombophilia. Thromb Haemost, 2001, 86, 92-103.
24. EMMERICH J., ROSENDAAL F.R., CATTANEO M., et al. - Combined effect of factor V Leiden and protheombin 20210A on the risk of venous thromboembolism. Pooled analysis of 8 case-control studies including 2 310 cases and 3 204 controls. Thromb Haemost, 2001, 86, 809-16.
25. ALHENC-GELAS M., ARNAUD E., NICAUD V., AUBRY M.L., FIESSINGER J.N., AIACH M., EMMERICH J. - Venous thromboembolic disease and the prothrombin, methylene tetrahydrofolate reductase and factor V genes. Thromb Haemost, 1999, 81, 506-10.
26. ALHENC-GELAS M., NICAUD V., GANDRILLE S., VAN DREDEN P., AMIRAL J., AUBRY M.L., et al. - The factor V gene A4070G mutation and the risk of venous thrombosis. Thromb Haemost, 1999, 81, 193-7.
27. AIACH M., NICAUD V., ALHENC-GELAS M., GANDRILLE S., ARNAUD E., AMIRAL J., et al. - Complex association of protein C gene promoter polymorphism with circulating protein C levels and the thrombotic risk. Arterioscl Thromb Vasc Biol, 1999, 19, 1573-6.
28. ARNAUD E., NICAUD V., POIRIER O., RENDU F., ALHENC-GELAS M., FIESSINGER J.N., et al. - Protective effect of a thrombin receptor (PAR-1) gene polymorphism towards venous thromboembolism. Arterioscl Thromb Vasc Biol, 2000, 20, 585-92.
29. ARNAUD E., BARBALAT V., NICAUD V., CAMBIEN F., EVANS A., MORRISON C., et al. - Polymorphisms in the 5′ regulatory region of the tissue factor gene and the risk of myocardial infarction and venous thromboembolism : the ECTIM and PATHROS studies. Arterioscl Thromb Vasc Biol, 2000, 20, 892-898.
30. LE FLEM L., PICARD V., EMMERICH J., GANDRILLE S., FIESSINGER J.N., AIACH M., ALHENC-GELAS M. - Mutations in promoter region of thrombomodulin and venous thromboembolic disease. Arterioscl Thromb Vasc Biol, 1999, 19, 1098-104.
31. ALHENC-GELAS M., RENY J.L., AUBRY M.L., AIACH M., EMMERICH J. - The FXIII Val 34 Leu mutation and the risk of venous thrombosis. Thromb Haemost (Letter), 2000, 84, 1117-8.
32. ARNAUD E., MOATTI D., EMMERICH J., DE PROST D. - No link between the TFPI V264M mutation and venous thromboembolic disease. Thromb Haemost (Letter), 1999, 82, 159-60.
33. ROSENDAAL F.R. - High levels of factor VIII and venous thrombosis. Thromb haemost, 2000, 83, 1-2.
34. VAN HYLCKAMA VLIEG A., VAN DER LINDEN I.K., BERTINA R.M., ROSENDAAL F.R. - High levels of factor IX increase the risk of venous thrombosis. Blood, 2000, 95, 3678-3682.
35. MEIJERS J.C.M., TEKELENBURG W.L.H., NOUMA B.N., BERTINA R.M., ROSENDAAL F.R. - High levels of coagulation factor XI as a risk factor for venous thrombosis. N Engl J Med, 2000, 342, 696-701.
36. HANKEY G.J., EIKELBOOM J.W. - Homocysteine and vascular disease. Lancet, 1999, 354, 407-13.
37. MILETICH J.P., PRESCOTT S.M., WHITE R., MAJERUS P.W., BOVILL E.G. - Inherited predisposition to thrombosis. Cell, 1993, 72, 477-480.
38. KOELEMAN B.P.C., REITSMA P.H., ALLAART C.F., BERTINA R.M. - Activated protein C resistance as an additional risk factor for thrombosis in protein C-deficient families. Blood, 1994, 84, 1031-1035.
39. KOELEMAN B.P.C., VAN RUMPT D., HAMULYAK K., REITSMA P.H., BERTINA R.M. - Factor V Leiden : an additional risk factor for thrombosis in protein S deficient families ? Thromb Haemost, 1995, 74, 580-583.
40. BORGEL D., DUCHEMIN J., ALHENC-GELAS M., MATHERON C., AIACH M., GANDRILLE S. - Molecular basis for protein S hereditary deficiency : genetic defects observed in 118 patients with type I and type IIa deficiencies. J Lab Clin Med, 1996, 128, 218-227.
41. GANDRILLE S., GREENGARD J.S., ALHENC-GELAS M., et al. - Incidence of activated protein C resistance caused by the ARG 506 GLN mutation in factor V in 113 unrelated symptomatic protein C-deficient patients. The French Network on the behalf of INSERM. Blood, 1995, 86, 219-24.
42. ZÖLLER B., SVENSSON P.J., HE X., DAHLBÉCK B. - Identification of the same factor V gene mutation in 47 out of 50 thrombosis-prone families with inherited resistance to activated protein C. J Clin Invest, 1994, 94, 2521-2524.
43. LE CAM-DUCHEZ V., GANDRILLE S., TREGOUET D., ALHENC-GELAS M., EMMERICH J., FIESSINGER J.N., et al. - Influence of three potential genetic risk factors for thrombosis in 43 families carrying the factor V Arg 506 to Gln mutation. Br J Haematol, 1999, 106, 889-897.
44. BOVILL E.G., HASSTEDT S.J., LEPPERT M.F., LONG G.L. - Hereditary thrombophilia as a model for multigenic disease. Thromb Haemost, 1999, 82, 662-6.
45. SELIGSOHN U., ZIVELIN A. - Thrombophilia as a multigenic disorder. Thromb Haemost, 1997, 78, 297-301.
46. PRANDONI P., LENSING A.W., COGO A. et al. - The long term clinical course of acute deep venous thrombosis. Ann Intern Med, 1996, 125, 1-7.
47. HANSSON P.O., SORBO J., ERIKSSON H. - Recurrent venous thromboembolism after deep vein thrombosis. Arch Intern Med, 2000, 160, 769-774.
48. Research Committee of the British Thoracic Society - Optimum duration of anticoagulation for deep vein thrombosis and pulmonary embolism. Lancet, 1992, 340, 873-6.
49. LEVINE M.N., HIRSH J., GENT M., et al. - Optimal duration of oral anticoagulant therapy : a randomized trial comparing four weeks with three months of warfarin in patients with proximal deep vein thrombosis. Thromb Haemost, 1995, 74, 606-11.
50. SIMIONI P., PRANDONI P., LENSING A.W., et al. - The risk of recurrent venous thromboembolism in patients with a mutation in the gene factor V. N Engl J Med, 1997, 336, 399-403.
51. EICHINGER S., PABINGER I., STUMPFLEN A., et al. - The risk of recurrent venous thromboembolism in patients with and without factor V leiden. Thromb Haemost, 1997, 77, 624-8.
52. DE STEFANO V., MARTINELLI I., MANNUCCI P.M., et al. - The risk of recurrent deep vein thrombosis among heterozygous carriers of both factor V leiden and the G20210A prothrombin mutation. N Engl J Med, 1999, 341, 801-6.
53. BOUNAMEAUX H. - Factor V Leiden paradox : risk of deep-vein thrombosis but not of pulmonary embolism. Lancet, 2000, 356, 182-3.
54. MEYER G., EMMERICH J., HELLEY D., et al. - Factors V Leiden and II 20210A in patients with symptomatic pulmonary embolism and deep vein thrombosis. Am J Med, 2001, 110, 12-5.